| Here you can request an informative letter that highlights many topics to use as a future reference. |
 |
|
|
|
|
|
|
|
|
|
|
|
 |
 |
|
|||||||||
 |
|
||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
 |
 |
 |
 |
 |
|
||||||
|
Articles and Resources
Pemetrexed Disodium and Either Gemcitabine or Carboplatin in Treating Patients With Advanced Malignant Pleural Mesothelioma Basic Trial Information Trial Description Purpose Eligibility Treatment/Intervention Trial Contact Information Alternative Title Phase II Randomized Study of Pemetrexed Disodium Combined With Either Gemcitabine or Carboplatin in Patients With Advanced Malignant Mesothelioma of the Pleura. Basic Trial Information
Trial Description Purpose: Drugs used in chemotherapy, such as pemetrexed disodium, gemcitabine, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether giving pemetrexed disodium with gemcitabine is more effective than giving pemetrexed disodium with carboplatin in treating malignant pleural mesothelioma. This randomized phase II trial is studying pemetrexed disodium and gemcitabine to see how well they work compared to pemetrexed disodium and carboplatin in treating patients with advanced malignant pleural mesothelioma. Eligibility: Eligibility criteria include the following: · At least 18 years old Final eligibility for a clinical trial is determined by the health professionals conducting the trial. For more details about the eligibility requirements for this trial and the treatment or intervention, refer to the Health Professional version of the trial summary. Treatment/Intervention: Patients will be randomly assigned (have an equal chance of being placed in one of two treatment groups). Patients in group one will receive an infusion of pemetrexed disodium and an infusion of carboplatin once in week 1. Patients in group two will receive an infusion of pemetrexed disodium as in group one. They will also receive an infusion of gemcitabine once in weeks 1 and 2. Treatment in both groups may repeat every 3 weeks for up to six courses. Beginning approximately 5-10 days before the start chemotherapy and continuing until approximately 3 weeks after the completion of chemotherapy, all patients will receive folic acid by mouth once a day. They will also receive an injection of vitamin B12 every 9 weeks. Patients will be evaluated every 3 months for 2 years and every 6 months for 1 year. Important: If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site. Trial Contact Information Trial Lead Organizations: Eastern Cooperative Oncology Group Nasser Hanna, MD, Protocol chair Corey Langer, MD, Protocol co-chair North Central Cancer Treatment Group Scott Okuno, MD, Protocol chair Trial Sites and Contacts: U.S.A. Delaware Lewes Beebe Medical Center Newark CCOP - Christiana Care Health Services Maryland Elkton MD Union Hospital Cancer Center at Union Hospital New Jersey East Orange Veterans Affairs Medical Center - East Orange New Brunswick Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School Red Bank Booker Cancer Center at Riverview Medical Center Voorhees Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees New York Bronx Albert Einstein Cancer Center at Albert Einstein College of Medicine Pennsylvania Danville Geisinger Medical Center State College Geisinger Medical Group Wilkes-Barre Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center ***Source: http://www.cancer.gov/clinicaltrials*** |